The European Association of Percutaneous Cardiovascular Interventions (EAPCI) has published a clinical guidance statement regarding the use of intra-coronary imaging (IC), sharing the document during its EuroPCR Annual Meeting, May 21-24 in Paris.

Significantly fewer renal and cardiac events are associated with angioplasty procedures using isosmolar contrast medium (IOCM) agent Visipaque (iodixanol) than those using low-osmolar contrast media (LOCM), demonstrate data from abstracts presented today at the EuroPCR Congress 2015 in Paris. 

REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") announced initial clinical results from patients treated with its ReZolve2 sirolimus-eluting bioresorbable coronary scaffold at Transcatheter Therapeutics 2013 ("TCT"), the world's leading interventional cardiology conference, which is being held this week in San Francisco, California. The ReZolve2 trial is currently enrolling up to 125 patients at multiple centers in Australia, Brazil, Europe, and New Zealand to provide the data needed to apply for European CE Marking. Patient enrollment was initiated in March 2013 and is currently ongoing.

Agfa HealthCare announces today that it will highlight its comprehensive IMPAX Cardiovascular suite of products at the EuroPCR congress, the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), from May 21-24, in Paris, France.

Optical coherence tomography (OCT) developer LightLab Imaging has launched its C7XR FD-OCT imaging system with the C7 Dragonfly Imaging Catheter at EuroPCR 2009 in Barcelona, Spain.

Two-year data from the SPIRIT III trial, Abbott’s U.S. pivotal trial,demonstrated that its Xience V everolimus-eluting coronary stent systemcontinues to deliver clinically superior benefits compared to BostonScientific’s Taxus paclitaxel-eluting coronary stent system, accordingto a presentation at a late-breaking clinical trials session at EuroPCR2008 in Barcelona, Spain.